Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143177 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
A Phase 2 study of Calcific Aortic Valve Disease, sponsored by REDNVIA Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT05143177: Recruiting Phase 2 study of Calcific Aortic Valve Disease, sponsored by REDNVIA Co..
NCT05143177 is a Phase 2 study of Calcific Aortic Valve Disease that is actively recruiting participants, run by REDNVIA Co.. The registered enrollment target is 580 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (336% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05143177, a Phase 2 study of Calcific Aortic Valve Disease, is actively recruiting participants, sponsored by REDNVIA Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Evogliptin
Study Locations (20)
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health System - Detroit
- Beaumont Hospital, Royal Oak - Royal Oak
Florida
- Mayo Clinic, FL - Jacksonville
- Baycare Health systems - Safety Harbor
New Jersey
- Hackensack Meridian Health - Hackensack
- Rutgers- Robert Wood Johnson Medical School - New Brunswick
New York
- Ichan School of Medicine - New York
- Stony brook - Stony Brook
Ohio
- Christ Hospital - Cincinnati
- OhioHealth Research Institute - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Mechanicsburg
- Einstein Medical Center Philadelphia - Philadelphia
Arizona
- Mayo Clinic, AZ - Phoenix
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
What NCT05143177 shows while recruiting
NCT05143177 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (336% higher).
The record links to 1 condition, with Calcific Aortic Valve Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05143177 names 20 study sites across 13 states, led by Michigan, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05143177 about?
NCT05143177 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)". This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to wh...
What is the current status of trial NCT05143177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 580 participants. The study started on 2022-06-27. Estimated completion is 2026-12-30.
What conditions does trial NCT05143177 study?
This clinical trial studies the following conditions: Calcific Aortic Valve Disease.
What interventions are being tested in trial NCT05143177?
The interventions under investigation include: Placebo (DRUG), Evogliptin (DRUG).
Who is sponsoring clinical trial NCT05143177?
This trial is sponsored by REDNVIA Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143177 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05143177's enrollment target sits among peer trials
580 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
- NCT06647303 · 580 participants · NA
Improving Surgical Communication for Patients in Wisconsin
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI